3
2
1

【The YinFeng Life Continuation Project Debuts at the 2026 Annual Meeting of the Chinese Medical Association's Medical Ethics Branch—Ethics Leading Biotech Toward Benevolent Innovation】

2026/07/22

The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.

Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross

2026/04/24

Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.

Yinfeng Life Science Research Institute, in Collaboration with University of Science and Technology of China, Develops CryoSIM Platform, Published in Top Analytical Chemistry Journal Revolutionizing Oocyte Membrane Permeability Analysis Technology

2026/03/04

The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

2026/02/02

On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).

World’s First Achievement Highlights Brand Leadership

2026/01/19

In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.

Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference

2026/01/04

Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.

2025-04-25

New Flexible Auditory Brainstem Implant Offers Hope for Patients with Severe Hearing Loss

A research team from the Swiss Federal Institute of Technology Lausanne (EPFL) recently published a groundbreaking achievement in Nature Biomedical Engineering: the world’s first flexible auditory brainstem implant (ABI). This innovative technology aims to address the side effects caused by the rigid structure of traditional ABIs, offering a more precise and safe hearing restoration solution for patients with severe cochlear nerve damage who cannot benefit from cochlear implants.

2025-04-25

Nature Medicine Review: AI Reconstructs the Paradigm of Drug Development

In the prolonged battle between humanity and disease, drug development remains the decisive battleground. Faced with the harsh reality of an average investment of $2.6 billion, a 15-year timeline, and a success rate below 10%, global scientists are turning to artificial intelligence (AI). This disruptive technology is quietly ushering drug development into a new era of "algorithm-driven" innovation. By 2025, the latest research in Nature journals reveals that generative AI models, exemplified by ChatGPT and Sora, are reshaping the entire drug development pipeline—from target discovery to clinical trials—accelerating "AI-driven drug discovery" from concept to clinical practice.

2025-04-18

Combat Effectiveness Boosted Fivefold! New "Smart" Immune Cells Precisely Target and Eliminate Cancer Cells

Imagine if immune cells in the human body could transform into "smart missiles," relentlessly tracking and destroying cancer cells without harming healthy tissue—this would revolutionize cancer treatment. A groundbreaking announcement from the USC Viterbi School of Engineering reveals the arrival of "EchoBack CAR T cells", a new breed of "thinking" immune warriors propelling targeted cancer therapy into a 2.0 era!

2025-04-17

Gene Scissors 2.0 Unveiled! New Tech Enables "Precision Gene Transplantation"

Nature hailed the breakthrough: "STITCHR fills critical technological gaps and heralds a new era of precision medicine." As clinical trials advance, this molecular revolution—orchestrated by RNA and jumping genes—is set to redefine humanity’s foundational approach to combating disease.

2025-04-11

Unlocking the "Gateway to Resurrecting Prehistoric Creatures": 12,500-Year-Extinct Dire Wolves Brought Back to Life

These advancements demonstrate the feasibility of gene-editing and cloning in resurrecting extinct species, attracting increased funding and scientific collaboration. This progress elevates genetic technology’s potential in biodiversity conservation, biopharmaceuticals, and beyond, heralding a new era of ecological restoration and innovation.

2025-04-11

Asia's First Xenotransplanted Kidney Recipient Exceeds 30 Postoperative Days, Meets Discharge Criteria

On April 8 (Tuesday), Xijing Hospital of Air Force Medical University announced a major breakthrough in Asia’s first gene-edited pig kidney transplant for a patient with end-stage renal disease. The patient has maintained stable kidney function for 32 days post-surgery and met discharge standards. This achievement marks a milestone in China’s clinical research on xenotransplantation, offering new hope for patients with terminal kidney disease.

< 1...171819...46 >
< 1234...28 >